JUL 15, 2026 · REGULATORY LABEL UPDATE
FDA supplemental approval: Repatha (Labeling)
U.S. Food and Drug Administration
FDA supplemental approval for labeling change to evolocumab; does not contain clinical trial data and conveys only that regulatory authorization was granted.
Reported
Approval status date2026-07-15
Active ingredient and strengthEvolocumab 140 mg/mL